Frankfurt, May 29,  2024 – McDermott Will & Emery advised STADA Arzneimittel AG on entering into an exclusive commercialization and license agreement with Bio-Thera Solutions. Ltd. for BAT2506, a biosimilar candidate to Simponi® (golimumab).

Under the agreement, Bio-Thera will maintain responsibility for the development, manufacturing and supply of BAT2506. STADA will receive exclusive rights to commercialize the product in the EU, the UK, Switzerland and selected other countries under its own marketing authorization.

Bio-Thera will receive payments, including development and commercialization milestones, of up to USD 157.5 million, subject to certain conditions being met.

Bio-Thera Solutions is a biopharmaceutical company based in Guangzhou, China, specializing in the development of novel therapeutics for, among others, the treatment of cancer, autoimmune and cardiovascular diseases as well as biosimilars for existing branded biologics.

STADA Arzneimittel AG, based in Bad Vilbel, Germany, focuses on a three-pillar strategy consisting of consumer healthcare products, generics and speciality pharma. The company sells products in around 115 countries worldwide. In the financial year 2023, STADA generated consolidated sales of EUR 3.73 billion, and employed over 11,600 people worldwide as of 31 December 2023.

The McDermott team advising STADA was led by counsel Monika Richter and included counsel Gary Howes, partner Deniz Tschammler, partner Henrik Holzapfel, counsel Laura Stammwitz, and associate Katharina Hoffmeister.

Frankfurt, May 29, 2024 – McDermott Will & Emery represents German lifespin GmbH, a pioneer in health status detection software, on forming a partnership with Acibadem University (ACU) and Acibadem Healthcare Group (AHG). The collaboration serves to launch a precision medicine initiative in the area of personalized healthcare.

Under the collaboration agreement, lifespin and ACU will combine their expertise to establish a state-of-the-art, AI-based metabolomics precision medicine platform. lifespin will offer their services across ACU’s extensive network through a Software as a Service (SaaS) model.

lifespin GmbH is a deep-data company that develops omni-intelligent health status assessment software enabled by proprietary AI algorithms. lifespin has built one of the largest databases of metabolomic health profiles across 240,000+ healthy and diseased individuals covering multiple age and biological sex groups as well as specific diseases in neurology, oncology, and inflammation.

Acibadem Healthcare Group was established in 1991, rapidly becoming one of the leading institutions in Turkey within the field of private healthcare services. Acibadem is part of the world’s second largest healthcare chain with its 24 hospitals and 15 outpatient clinics, as well as 7 cancer centers.

The McDermott team was led by partner Deniz Tschammler and comprised partners Jana Grieb and Florian Lechner, counsel Markus Fischer as well as associates Lea Hachmeister and Katharina Hoffmeister.

Munich, May 24, 2024 – With a team led by Holger Ebersberger and Thomas Diekmann, McDermott Will & Emery represented Levine Leichtman Capital Partners-backed cleversoft Group on its acquisition of tetralog systems AG.

The acquisition enhances cleversoft’s service portfolio with WealthTech solutions for portfolio analysis and optimization, supporting its broader expansion strategy.

Founded in 2004 and headquartered in Munich, cleversoft is a leading provider of regulatory financial services technology. The group provides over 1,000 financial institutions worldwide with solutions to optimize business-relevant compliance processes.

Tetralog systems AG has been digitizing the investment advisory process for financial institutions in Europe for more than 30 years. Its customers include renowned Tier 1 banks and asset managers. As part of cleversoft Group, tetralog systems will continue to operate in the market under its traditional name.

Levine Leichtman Capital Partners (LLCP) acquired cleversoft from Main Capital in 2023. A team from McDermott Will & Emery also advised on this transaction.

The McDermott team was led by Holger H. Ebersberger and Thomas Diekmann and included Marion Dalvai-König, Armin Teymouri, Steffen Woitz, Lukas Deutzmann, Claus Färber, Florian Schiefer and Christian Rolf.